Tumor molecular profiling of NSCLC patients using next generation sequencing

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Non-small cell lung cancer (NSCLC) is the most common lung cancer subtype.
• Targeted therapies are crucial for NSCLC management, necessitating precise molecular profiling.
• Next-generation sequencing (NGS) is a key technology for tumor characterization.

Purpose of the Study:

• To evaluate the performance of custom targeted gene panels for NSCLC molecular profiling.
• To determine the mutation spectrum in a cohort of 502 NSCLC patients.
• To assess the utility of NGS in identifying actionable mutations for personalized treatment.

Main Methods:

• Utilized a custom 23-gene multiplex amplification hotspot panel for DNA analysis from FFPE tissues.
• Employed the Ion AmpliSeq™ RNA Fusion Lung Cancer Research Panel for RNA fusion transcript analysis.
• Analyzed tumor DNA and RNA from 502 NSCLC patients.

Main Results:

• The DNA panel demonstrated 100% sensitivity, specificity, and reproducibility at 3% allelic frequency.
• DNA mutations were found in 74.5% of patients, and RNA fusions in 3.2%.
• Alterations in cancer-driver genes were identified in 77.6% of tumors, with 23% having mutations actionable by targeted or emerging therapies.

Conclusions:

• Targeted NGS panels are reliable tools for comprehensive tumor molecular profiling in NSCLC.
• This approach facilitates personalized treatment decision-making by identifying targetable genetic alterations.
• The study highlights the high prevalence of actionable mutations in NSCLC, underscoring the importance of molecular characterization.